We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Viking Therapeutics Inc is a biotechnology business with stocks listed in the US. Viking Therapeutics shares (VKTX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$5.76 – a decrease of 4.16% over the previous week. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | US$5.12 - US$10.09 |
|---|---|
| 50-day moving average | US$6.3146 |
| 200-day moving average | US$6.0498 |
| Target price | US$20.1 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | US$-0.666 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $5.76
| 1 week (2021-10-14) | -6.34% |
|---|---|
| 1 month (2021-09-24) | -11.11% |
| 3 months (2021-07-23) | -0.17% |
| 6 months (2021-04-23) | -4.32% |
| 1 year (2020-10-23) | 0.70% |
|---|---|
| 2 years (2019-10-24) | -10.84% |
| 3 years (2018-10-24) | -53.55% |
| 5 years (2016-10-24) | 443.40% |
| Gross profit TTM | US$0 |
|---|---|
| Return on assets TTM | -12.49% |
| Return on equity TTM | -20.38% |
| Profit margin | 0% |
| Book value | 2.877 |
| Market capitalisation | US$450.4 million |
TTM: trailing 12 months
There are currently 5.1 million Viking Therapeutics shares held short by investors – that's known as Viking Therapeutics's "short interest". This figure is 13.4% down from 5.9 million last month.
There are a few different ways that this level of interest in shorting Viking Therapeutics shares can be evaluated.
Viking Therapeutics's "short interest ratio" (SIR) is the quantity of Viking Therapeutics shares currently shorted divided by the average quantity of Viking Therapeutics shares traded daily (recently around 695147.39726027). Viking Therapeutics's SIR currently stands at 7.3. In other words for every 100,000 Viking Therapeutics shares traded daily on the market, roughly 7300 shares are currently held short.
However Viking Therapeutics's short interest can also be evaluated against the total number of Viking Therapeutics shares, or, against the total number of tradable Viking Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Viking Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Viking Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0763% of the tradable shares (for every 100,000 tradable Viking Therapeutics shares, roughly 76 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Viking Therapeutics.
Find out more about how you can short Viking Therapeutics stock.
We're not expecting Viking Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Viking Therapeutics's shares have ranged in value from as little as US$5.12 up to US$10.09. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Viking Therapeutics's is 1.8175. This would suggest that Viking Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Shares in the wealth management giant have been largely stable in the last 6 months.
Everything we know about the Judo Capital Holdings IPO, plus information on how to buy in.
Everything we know about the Alloggio Group IPO, plus information on how to buy in.
Everything we know about the Larvotto Resources IPO, plus information on how to buy in.
Everything we know about the Vulcan Steel IPO, plus information on how to buy in.
Everything we know about the Artrya IPO, plus information on how to buy in.
Everything we know about the 8 Au IPO, plus information on how to buy in.
Everything we know about the Radiopharm Theranostics IPO, plus information on how to buy in.
The online retailer’s shares have lost more than half their value in the last 12 months.
